An expanded access record providing Burosumab in X-linked Hypophosphatemia and Tumor-Induced Osteomalacia, sponsored by Kyowa Kirin Co., Ltd.. Available. Per ClinicalTrials.gov, last updated 2025-03-05.
Sponsored by Kyowa Kirin Co., Ltd. · Expanded access
Individual patient expanded access requests may be considered for patients who have no other treatment options
Expanded access may be available outside of the US in countries prior to approval by the local regulatory agencies. For full details, please visit the links provided below.
49 studies on the registry are indexed under Familial Hypophosphatemic Rickets; 8 are open to participants now.
Browse Familial Hypophosphatemic Rickets studies →Kyowa Kirin Co., Ltd. is the lead sponsor of 159 studies on the registry; 8 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria:
-
Exclusion Criteria:
-
Also known as: UX023, Crysvita®, KRN23
No study locations are listed for this record.
Expanded access is arranged between your doctor and the company. Ask your care team to contact the provider listed on this record.
Contact the providerGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Familial Hypophosphatemic Rickets →